EXT1-high tumors may be vulnerable to synthetic lethality approaches involving checkpoint inhibition (CHK1 or ATR inhibitors), whereas EXT2-driven gliomas might respond to combinatorial regimens targeting cytoskeletal remodeling or focal adhesion dynamics 73-75. The gene discussed is EXT2; the disease is central nervous system cancer.